Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 160

1.

Evaluation of the clinical benefit of long-term (beyond 2 years) treatment of skeletal-related events in advanced cancers with zoledronic acid.

Henk H, Teitelbaum A, Kaura S.

Curr Med Res Opin. 2012 Jul;28(7):1119-27. doi: 10.1185/03007995.2012.689254. Epub 2012 May 17.

PMID:
22536885
2.
3.

Retrospective evaluation of the clinical benefit of long-term continuous use of zoledronic acid in patients with lung cancer and bone metastases.

Henk HJ, Kaura S, Teitelbaum A.

J Med Econ. 2012;15(1):195-204. doi: 10.3111/13696998.2011.650489. Epub 2011 Dec 23.

PMID:
22175657
4.

Assessment of zoledronic acid treatment patterns and clinical outcomes in patients with bone metastases from genitourinary cancers.

Henk HJ, Kaura S.

J Med Econ. 2012;15(1):185-94. doi: 10.3111/13696998.2011.649324. Epub 2011 Dec 23.

PMID:
22168786
5.

Persistency with zoledronic acid is associated with clinical benefit in patients with multiple myeloma.

Henk HJ, Teitelbaum A, Perez JR, Kaura S.

Am J Hematol. 2012 May;87(5):490-5. doi: 10.1002/ajh.23164. Epub 2012 Mar 27.

6.

Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion.

Rosen LS, Gordon DH, Dugan W Jr, Major P, Eisenberg PD, Provencher L, Kaminski M, Simeone J, Seaman J, Chen BL, Coleman RE.

Cancer. 2004 Jan 1;100(1):36-43.

7.

Zoledronic acid: multiplicity of use across the cancer continuum.

Lipton A.

Expert Rev Anticancer Ther. 2011 Jul;11(7):999-1012. doi: 10.1586/era.11.71. Review.

PMID:
21806323
8.

Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.

Ibrahim A, Scher N, Williams G, Sridhara R, Li N, Chen G, Leighton J, Booth B, Gobburu JV, Rahman A, Hsieh Y, Wood R, Vause D, Pazdur R.

Clin Cancer Res. 2003 Jul;9(7):2394-9.

10.
11.

Prolonged administration of bisphosphonates is well-tolerated and effective for skeletal-related events in Chinese breast cancer patients with bone metastasis.

Ding X, Fan Y, Ma F, Li Q, Wang J, Zhang P, Yuan P, Xu B.

Breast. 2012 Aug;21(4):544-9. doi: 10.1016/j.breast.2012.04.008. Epub 2012 May 22.

PMID:
22627092
12.

Bisphosphonates: clinical experience.

Coleman RE.

Oncologist. 2004;9 Suppl 4:14-27. Review.

13.

Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastases.

Tunn UW, Stenzl A, Schultze-Seemann W, Strauss A, Kindler M, Miller K, Wirth MP, Zantl N, Schulze M, May C, Ruebel A, Birkholz K, Gruenwald V.

Can J Urol. 2012 Jun;19(3):6261-7.

PMID:
22704310
14.

Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid.

Lipton A, Colombo-Berra A, Bukowski RM, Rosen L, Zheng M, Urbanowitz G.

Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6397S-403S. Review.

15.
16.

Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial.

Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, De Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman J.

Cancer. 2004 Jun 15;100(12):2613-21.

17.

The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.

Lipton A, Small E, Saad F, Gleason D, Gordon D, Smith M, Rosen L, Kowalski MO, Reitsma D, Seaman J.

Cancer Invest. 2002;20 Suppl 2:45-54. Review.

PMID:
12442349
18.

Cost-effectiveness of zoledronic acid in the management of skeletal metastases in patients with lung cancer in France, Germany, Portugal, the Netherlands, and the United kingdom.

Joshi AD, Carter JA, Botteman MF, Kaura S.

Clin Ther. 2011 Mar;33(3):291-304.e8. doi: 10.1016/j.clinthera.2011.04.002.

PMID:
21600384
19.

Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer.

Crawford BS, McNulty RM, Kraut EH, Turowski RC.

Cancer Invest. 2009 Dec;27(10):984-8. doi: 10.3109/07357900902783203.

PMID:
19909013
20.

Osteoporosis. Letter to the editor.

Namazi H.

Curr Med Res Opin. 2012 Nov;28(11):1755. doi: 10.1185/03007995.2012.728526. Epub 2012 Sep 25. No abstract available.

PMID:
22978776

Supplemental Content

Support Center